Exclusive Summary

• This Olanzapine Orally Disintegrating Tablet is registered in the US FDA and holds US FDA GMP certification, ensuring high quality assurance and compliance for global market access.
• The ODT dosage form improves patient adherence, especially for psychiatric patients with dysphagia or who refuse medication, indicating significant market demand potential globally due to high prevalence of mental illnesses.
• The original drug's patent has long expired, leading to a mature generic market, but ODTs still occupy a specific niche as a differentiated dosage form.
• Olanzapine is listed in the WHO Essential Medicines List and widely recommended as a first or second-line treatment for schizophrenia and bipolar disorder, signifying high clinical value and broad global acceptance.
• Compared to the originator drug, it offers a significant cost advantage, enabling partner pharmaceutical companies to achieve larger market shares in low- and middle-income countries or under healthcare cost containment policies.